Evidence map›Paper›PMID 37316966›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023

HCV Core Protein-ISX Axis Promotes Chronic Liver Disease Progression via Metabolic Remodeling and Immune Suppression.

Li-Ting Wang, Shen-Nien Wang, Shyh-Shin Chiou, Jhih-Peng Tsai, Chee-Yin Chai, Li-Wen Tseng, Jin-Ching Lee, Ming-Hong Lin, Shau-Ku Huang, Shih-Hsien Hsu

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of PD‑1/PD‑L1 axis in liver diseases.Clinical and experimental medicine · 2025
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Li-Ting WangDepartment of Life Science, National Taiwan Normal University, Taipei, 116059, Taiwan.
Shen-Nien WangGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Shyh-Shin ChiouCenter of Applied Genomics, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Jhih-Peng TsaiCenter of Applied Genomics, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Chee-Yin ChaiDepartment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, 80708, Taiwan.
Li-Wen TsengGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.
Jin-Ching LeeDepartment of Biotechnology, College of Life Science, National Sun Yat-sen University, Kaohsiung, 804201, Taiwan.
Ming-Hong LinDepartment of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, 80708, Taiwan.
Shau-Ku HuangNational Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli County, 35053, Taiwan.
Shih-Hsien HsuGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, 80708, Taiwan.ORCID 0000-0003-2102-0505
Kaohsiung Medical University · TWJohns Hopkins University · USNational Sun Yat-sen University · TWNational Taiwan Normal University · TW

Funding

Kaohsiung Medical University DK(A)112002Kaohsiung Medical University KMU-DK108012Kaohsiung Medical University Hospital KMUH106-6R33Kaohsiung Medical University Hospital KMUH107-7R34Kaohsiung Medical University Hospital KMUH107-7R46Ministry of Science and Technology, Taiwan 109-2326-B-003-001-MY3Ministry of Science and Technology, Taiwan 110-2314-B-037-072-MY3Ministry of Science and Technology, Taiwan 111-2320-B-037-031Ministry of Science and Technology, Taiwan MOST108-2314-B-037-065-MY3National Health Research Institutes EO-111-PP10-014National Science and Technology Council, Taiwan NSTC-111-2320-B-400 -026Shenzhen Science and Technology Peacock Team Project KQTD20170331145453160
6 · The paper itself

Abstract

Chronic hepatitis C virus (HCV) infection is an important public health issue. However, knowledge on how the virus remodels the metabolic and immune response toward hepatic pathologic environment is limited. The transcriptomic and multiple evidences reveal that the HCV core protein-intestine-specific homeobox (ISX) axis promotes a spectrum of metabolic, fibrogenic, and immune modulators (e.g., kynurenine, PD-L1, and B7-2), regulating HCV-infection relevant pathogenic phenotype in vitro and in vivo. In a transgenic mice model, the HCV core protein-ISX axis enhance metabolic disturbance (particularly lipid and glucose metabolism) and immune suppression, and finally, chronic liver fibrosis in a high-fat diet (HFD)-induced disease model. Mechanistically, cells with HCV JFH-1 replicons upregulate ISX and, consequently, the expressions of metabolic, fibrosis progenitor, and immune modulators via core protein-induced nuclear factor-κB signaling. Conversely, cells with specific ISX shRNAi inhibit HCV core protein-induced metabolic disturbance and immune suppression. Clinically, the HCV core level is significantly correlated with ISX, IDOs, PD-L1, and B7-2 levels in HCC patients with HCV infection. Therefore, it highlights the significance of HCV core protein-ISX axis as an important mechanism in the development of HCV-induced chronic liver disease and can be a specific therapeutic target clinically.

Indexed as

Carcinoma, HepatocellularHepatitis CHepatitis C, ChronicLiver NeoplasmsAnimalsB7-H1 AntigenDisease ProgressionMiceMice, TransgenicB7-H1 AntigenHCV core proteinimmune suppressionISXmetabolic dysregulationprogrammed death-ligand 1 (PD-L1)

Identifiers

PMID37316966
PMCPMC10427408
OpenAlexW4380681363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.